. 2012 Nov 15;23(12):2061–2071. doi: 10.1681/ASN.2012070664

Table 1.

Characteristics of patient cohorts in the individual studies included in the analysis

Study, Year	Patients (n)	Age (yr)	Women (%)	Black (%)	First Transplant (%)	Follow-up Period (mo)	Patients with Living Donors (%)
Group 1
Patel et al., 2007⁸	20 DSA+	48.6^a	45	35	NA	8.2^a	100
Patel et al., 2007⁸	40 DSA−	54.1^a	42.5	25	NA	11.1^a	100
Gupta et al., 2008⁶	16 DSA+	50.1^b	60	NA	79		NA
Gupta et al., 2008⁶	95 DSA−	44	32^d	NA	91^d	12 and 60^c	NA
Vlad et al., 2009¹⁰	13 DSA+	52^b	38%	NA	80%
Vlad et al., 2009¹⁰	265 DSA−	52^b	38%	NA	80%	48	0
Couzi et al., 2011⁵	18 DSA+
Couzi et al., 2011⁵	39 DSA−	46.57^b	44.40	0	34	32.52^b	0
Willicombe et al., 2011¹¹	45 DSA+	47.2^b	53.30	15.60	57.80	22.68^b	55.6
Willicombe et al., 2011¹¹	435 DSA−	47.4^b	32.4^d	12.60	91.7^d	23.52^b	45.3
Verghese et al., 2010⁹	10 DSA+	16.3^b	50	10		33.6^b	20
Verghese et al., 2010⁹	72 DSA−	15.1^b	45.80	5.60		39.6^b	43.1
Higgins et al., 2011⁷	23 DSA+	46.3^b	65.20	NA	57.00	39.6^b	87
Higgins et al., 2011⁷	28 DSA−	44.2^b	53.60	NA	61	39.6^b	50
Group 2
Gibney et al., 2006¹⁵	20 DSA+
Gibney et al., 2006¹⁵	35 DSA−	48.9^b^,^e	62 F^e	9^e	75^e	6^b	39^e
van den Berg-Loonen et al., 2008¹⁸	13 DSA+	51^a	62	NA	54	96^f	0
van den Berg-Loonen et al., 2008¹⁸	14 DSA−	51.5^a	64	NA	36	96^f	0
Aubert et al., 2009¹³	11 DSA+	42.8^b	73	NA	NA	12^f	36
Aubert et al., 2009¹³	102 DSA−	46.6^b	26	NA	NA	12^f	40
Amico et al., 2009¹²	67 DSA+	47^b	57	NA	55		48
Amico et al., 2009¹²	267 DSA−	52^a	31	NA	91	60 mo^f and 200 d^g	55
Mahmoud et al., 2009¹⁷	16 DSA+	30.3^b	31.25	NA	100		100
Mahmoud et al., 2009¹⁷	137 DSA−	28.7^b	24.00	NA	100.00	3^f	100
Lefaucheur et al., 2010¹⁶	76 DSA+	NA	NA	NA	NA	51.4^b; 96^f	0
Lefaucheur et al., 2010¹⁶	326 DSA−	NA	NA	NA	NA	96^f	0
Dunn et al., 2011¹⁹	46 DSA+	42.5^b	61	24ⁱ	56	56^a	36.8
Dunn et al., 2011¹⁹	541 DSA−	42.8–47.4^b	40.8	14.8	74	43.8–51^a	70
Caro-Orleas et al., 2012¹⁴	103 DSA+	47^a	75.70	NA	60	62.5^a	0
Caro-Orleas et al., 2012¹⁴	780 DSA−	48^a	37	NA	92	73.5^a	0
Group 3
Bielmann et al., 2007²⁶	9 DSA+	48^a	67	NA	44		22
Bielmann et al., 2007²⁶	56 DSA−	53^a	36	NA	91		57
Billen et al., 2009²⁷	32 DSA+	57	25	NA	78	6.9^a
Billen et al., 2009²⁷	133 DSA−	53	41	NA	82	7.5^a
Morris et al., 2010²⁸	15 DSA+						100
Morris et al., 2010²⁸	134 DSA−	47.5^b	42	6	87.90	18^h	100
Group 4
Vlad et al., 2009¹⁰	14 DSA+	52^b^,^e	38%	NA	Majority		0
Vlad et al., 2009¹⁰	33 DSA−	52^b^,^e	38%	NA	Majority	48	0
Higgins et al., 2011⁷	44 DSA+	43.4^b	75	NA	30		93
Higgins et al., 2011⁷	28 DSA−	44.2^b	53.60	NA	61	39.6^b	50

NA, not available.

Median.

Mean.

Time intervals at which data are reported.

Estimate of percent female.

Data for entire cohort reported.

Maximum duration of follow-up for allograft survival.

Maximum duration of follow-up for AMR.

Minimum follow-up period.

ⁱ

Nonwhite.